Ritonavir

證據等級: L5 預測適應症: 3

目錄

  1. Ritonavir
  2. Ritonavir: Evaluation Report — Insufficient TxGNN Prediction Data
    1. One-Sentence Summary
    2. Quick Overview
    3. Safety Considerations
    4. Conclusion and Next Steps
    5. Disclaimer

## 藥師評估報告

Ritonavir: Evaluation Report — Insufficient TxGNN Prediction Data

One-Sentence Summary

Ritonavir is an HIV protease inhibitor widely used as a pharmacokinetic booster in combination antiviral regimens (e.g., Paxlovid, lopinavir/ritonavir). The current Evidence Pack contains no TxGNN-predicted new indications, and the drug is not registered in Taiwan. Due to critical data gaps across prediction, regulatory, mechanism, and safety dimensions, a full repurposing evaluation cannot be completed at this stage.


Quick Overview

Item Content
Original Indication HIV infection (general pharmaceutical knowledge; absent from regulatory data)
Predicted New Indication Not available
TxGNN Prediction Score Not available
Evidence Level Undetermined — no prediction data present
Taiwan Market Status ✗ Not marketed
Number of Authorizations 0
Recommended Decision Hold

Safety Considerations

No safety data is available for this Evidence Pack. All warning, contraindication, and drug interaction fields returned as empty or missing.

Please refer to the package insert for safety information.


Conclusion and Next Steps

Decision: Hold

Rationale: The Evidence Pack for Ritonavir is critically incomplete across all four evaluation dimensions — TxGNN prediction, regulatory status, mechanism of action, and safety profile. Without a predicted indication to evaluate, no repurposing case can be constructed or assessed.

To proceed, the following is needed:

  • TxGNN prediction resultspredicted_indications must be populated with at least one candidate indication and associated evidence (clinical trials, literature)
  • Mechanism of action (MOA) — retrieve from DrugBank API (DG002: High severity gap)
  • Package insert safety data — key warnings, contraindications, and drug interactions from TFDA or equivalent source (DG001: Blocking severity gap)
  • Original indication confirmation — verify approved indications from Taiwan TFDA or international regulatory sources (EMA/FDA)
  • Drug interaction profile — DDI query returned not_found; re-query with alternate sources (e.g., DrugBank DDI, clinical pharmacology databases)

    Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.



Back to top

Copyright © 2026 藥提醒科技有限公司 (yao.care). This report is for research purposes only and does not constitute medical advice.

This site uses Just the Docs, a documentation theme for Jekyll.